CytoDyn (CYDY) Other Non-Current Liabilities (2014 - 2026)
CytoDyn's (CYDY) quarterly Other Non-Current Liabilities came in at $43.6 million in Q1 2026, little changed YoY from $43.6 million in Q1 2025, and little changed on a QoQ basis from $43.6 million in Q4 2025.
CytoDyn (CYDY) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
CytoDyn (CYDY) has 11 years of Other Non-Current Liabilities data on file, last reported at $43.6 million in Q1 2026.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $43.6 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $43.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $43.6 million, changed 0.0% from the prior year.
- Other Non-Current Liabilities steadied at $43.6 million in Q1 2026, from $43.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $43.6 million in Q2 2024 to a low of $33000.0 in Q4 2023.
- A 4-year average of $29.7 million and a median of $43.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 131933.33% — and 2025, when it changed 0.0%.
- Tracing CYDY's Other Non-Current Liabilities over 4 years: stood at $33000.0 in 2023, then soared by 131933.33% to $43.6 million in 2024, then changed by 0.0% to $43.6 million in 2025, then changed by 0.0% to $43.6 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $43.6 million (Q1 2026), $43.6 million (Q4 2025), and $43.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 43.57 Mn |
| Nov 30, 2025 | 43.57 Mn |
| Aug 31, 2025 | 43.57 Mn |
| May 31, 2025 | 43.57 Mn |
| Feb 28, 2025 | 43.57 Mn |
| Nov 30, 2024 | 43.57 Mn |
| Aug 31, 2024 | 43.57 Mn |
| May 31, 2024 | 43.57 Mn |
| Feb 29, 2024 | 3.49 Mn |
| Nov 30, 2023 | 33,000.00 |
| Aug 31, 2023 | 4.38 Mn |
| May 31, 2023 | 79,000.00 |
| Feb 29, 2020 | 2.11 Mn |
| Nov 30, 2019 | 1.58 Mn |
| Aug 31, 2019 | 1.78 Mn |
| May 31, 2019 | 402,000.00 |
| Feb 28, 2019 | 2.83 Mn |
| Nov 30, 2018 | 2.83 Mn |
| Aug 31, 2018 | 2.07 Mn |
| May 31, 2018 | 1.32 Mn |